Luca G. Guidotti (LGG) is an immunopathologist, virologist and drug hunter of international renown who spent more than twenty years as part of the Faculty of Scripps Research in La Jolla, California (where he remains an Adjunct Professor). LGG currently serves as Deputy Scientific Director of IRCCS San Raffaele Hospital and Full Professor of Pathology at the Vita-Salute San Raffaele University in Milan, Italy. Recognized for his groundbreaking research on hepatitis B virus (HBV) infection, LGG's seminal contributions have been published in prestigious journals such as Cell, Nature or Science (see rb.gy/hvcq8z). His research endeavors have garnered robust support from institutions such as the NIH, ERC and numerous biotech and pharmaceutical companies. Notably, this work has played a pivotal role in advancing the development and subsequent approval of direct-acting antivirals (DAAs) for the treatment of chronic HBV infection. LGG has served on multiple Study Sections and Panels at both the NIH and ERC, guiding the allocation of research funds. Additionally, he is a member of the "Comitato Tecnico Scientifico (CTS)" at the Italian Ministry of Health. Beyond academia, LGG lends his expertise as a Scientific Advisory Board Member to numerous biotech and pharma companies and holds or has held Directorial Board positions in various foundations and both private and publicly traded (Nasdaq) companies. Lastly, LGG contributions extend to being an inventor on many international patents.

Click here to view our publications